Effect of Turmacin supplementation on joint discomfort and functional outcome among healthy participants - A randomized placebo-controlled trial
| Autor: | Sreejith Bhaskaran, Pranathi Racha, Jeffrey Pradeep Raj, Rajkumar S Amaravati, Shreeraam Venkatachalam |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Complementary and Manual Therapy
Adult Male medicine.medical_specialty Adolescent Knee Joint Visual analogue scale Placebo-controlled study Placebo 03 medical and health sciences Young Adult 0302 clinical medicine Curcuma Double-Blind Method Threshold of pain Medicine Humans Pain Management 030212 general & internal medicine Muscle Strength Range of Motion Articular Adverse effect Survival analysis Pain Measurement Advanced and Specialized Nursing business.industry Plant Extracts Middle Aged Arthralgia Healthy Volunteers Clinical trial Complementary and alternative medicine Physical therapy Female business 030217 neurology & neurosurgery |
| Zdroj: | Complementary therapies in medicine. 53 |
| ISSN: | 1873-6963 |
| Popis: | Objective Curcuma longa has been widely used in Ayurveda for its medicinal properties and Turmacin was developed from C. longa as a standardized extract containing turmerosaccharides. In this clinical trial, the effect of Turmacin on knee joint discomfort in healthy adults subjected to strenuous physical activity was evaluated. Design Double-blind, triple-arm, parallel-group, randomized placebo-controlled trial. Setting Healthy participants from an urban tertiary care teaching hospital. Intervention Healthy participants were randomized in 1:1:1 ratio to receive either Turmacin 0.5 g/1 g or placebo once daily for 84 days. The participants were subjected to 10-minute strenuous exercise. Outcome measures Time to initial pain, final pain score on a visual analogue scale, range of movement (ROM) of knee and the force of contractions of muscles around the knee joint. Results A total of n = 90 participants were recruited. The mean final pain scores were significantly lower in the Turmacin 1 g and Turmacin 0.5 g when compared with the placebo from day-7 and day-5 onwards respectively. The survival analysis consistently showed a decreased hazard for early onset of pain in both the Turmacin groups. On day-84, the difference in mean ROM between Turmacin 0.5 g and placebo was 4.79 degrees (p = 0.008) and that for Turmacin 1 g and placebo was 2.34 degrees (p = 0.306). The difference in muscle force for isokinetic contractions of the quadriceps at angular velocities of 120 and 180 was significant between Turmacin 0.5 g and placebo (p = 0.002 and p = 0.005 respectively) while that for Turmacin 1 g & Turmacin 0.5 g (p = 0.206 and p = 0.414 respectively) and Turmacin 1 g & Placebo (p = 0.046 and p = 0.037) were not significant. However, in the within group analysis participants in Turmacin 1 g group had better preserved muscle functions than Turmacin 0.5 g group at angular velocities of 120 and 180 when compared with placebo. Conclusion Turmacin (0.5 g and 1 g) was efficacious when compared to placebo in increasing the pain threshold and knee ROM in healthy participants with minor adverse events. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect